The landscape of pharmaceutical safety assessment is undergoing a profound metamorphosis. For decades, the industry has relied on a rigid, animal-centric paradigm that, while foundational, has increasingly struggled to keep pace with the complexities of human biology. Today, the rise of New Approach Methodologies (NAMs)—specifically functional, human-relevant assays—marks the most significant shift in drug development since the mid-20th century.
While the 2022 signing of the FDA Modernization Act 2.0 served as a high-profile catalyst, framing the shift as a sudden legislative "overnight" success ignores the arduous, decade-long journey of scientific validation that preceded it. This transition is not a disruption imposed by policy; it is an evolution driven by the undeniable performance of human-derived models in predicting cardiac risk.
The Chronology of a Paradigm Shift
The journey toward modern cardiac safety assessment began in earnest during the early 2010s, born from a frustration with the high rate of late-stage drug attrition due to safety liabilities. Traditional models often failed to translate to human outcomes, leading to costly delays or, worse, safety failures in clinical trials.
The Foundation: Tox21 and the CiPA Initiative
The movement gained early momentum through initiatives like Tox21 and ToxCast, which introduced the concept of high-throughput, mechanism-based screening. However, the true turning point for cardiac safety was the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative. CiPA challenged the industry to look beyond traditional hERG-channel screening and animal models, proposing that human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) could provide more accurate, human-relevant data.
Bridging the Gap: Regulatory Engagement
Throughout the mid-2010s, adoption remained cautious. Pharmaceutical companies were eager to utilize these tools internally, but the lack of a clear regulatory pathway created a "validation paradox." The solution arrived in the form of the FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. By creating a structured dialogue between developers and regulators, ISTAND allowed the industry to define what "fit-for-purpose" evidence looks like, turning experimental technologies into credible regulatory tools.
The Mechanics of Maturity: MEA and iPSC Technology
At the heart of this success story is the marriage of human iPSC-derived cardiomyocytes with Microelectrode Array (MEA) technology. Unlike traditional assays that provide static snapshots, platforms like the Maestro MEA enable continuous, noninvasive, and real-time monitoring of cardiac electrophysiology.
Why MEA is the Gold Standard
The primary challenge in cardiac safety is identifying the risk of torsades de pointes—a lethal ventricular arrhythmia. Traditional animal models, while standardized, do not always mirror human cardiac ion channel sensitivity. MEA technology, however, provides a functional readout of the entire cellular action potential. Because these assays utilize human cells, they inherently incorporate human-specific genetic and physiological nuances, providing a level of predictive power that animal models simply cannot replicate.
Standardization: The AIMS Initiative
As these technologies moved from academic curiosity to industry staples, a new challenge emerged: consistency. Variability between different stem cell lines or experimental protocols threatened to undermine the credibility of NAM data. To address this, the Axion iPSC Model Standards (AIMS) initiative was launched. By bringing together leaders from across the safety field, AIMS aims to define the benchmarks for baseline electrophysiological performance. This standardization is the "final frontier" for NAMs, ensuring that data generated in a lab in Europe is as reliable and comparable as data generated in a facility in the United States.
Supporting Data: Evidence of Efficacy
The shift toward NAMs is supported by an expanding body of empirical evidence. A pivotal 2025 study led by FDA scientists highlighted a dramatic increase in the inclusion of hiPSC-CM data in Investigational New Drug (IND) applications. Between 2020 and 2023, the number of submissions incorporating hiPSC-CM MEA assays doubled compared to the total number from the entire preceding decade.
Performance Against Benchmarks
New research, currently under peer review, suggests that hiPSC-CM data not only shows high concordance with clinical QT outcomes but frequently outperforms traditional hERG assays and animal QT studies in predictive accuracy. Specifically, when used in combination with other in vitro assays, hiPSC-CM models have demonstrated a significant reduction in "false negatives"—cases where a drug might have been prematurely discarded or, conversely, moved forward with hidden risks.
The voluntary uptake of these assays is perhaps the most compelling metric of success. Despite the fact that hiPSC-CM data is not currently a mandatory regulatory requirement for IND submissions, sponsors are increasingly choosing to include them. Today, at least 16 major contract research organizations (CROs) offer CiPA-style hiPSC-CM assays as a standard service, indicating that the industry views these tools not as a compliance burden, but as a competitive advantage in de-risking drug candidates.
Official Responses and Regulatory Outlook
The FDA’s stance on NAMs has evolved from cautious observation to active participation. Through programs like ISTAND, regulators have signaled that they are not merely waiting for industry data—they are actively collaborating to shape the standards that will govern future drug development.
The acceptance of a letter of intent from Axion BioSystems for an iPSC-CM MEA assay into the ISTAND program serves as a milestone. It acknowledges that the industry has moved past the "concept" phase and is now effectively scaling "fit-for-purpose" tools. For regulators, the goal is clear: to maintain high safety standards while reducing the reliance on models that provide limited translational value.
Implications for Safety Leaders
For those at the helm of pharmaceutical safety organizations, the current "inflection point" represents a critical juncture. The implication is clear: the risk is no longer in adopting new technology, but in failing to do so.
Navigating the Transition
Safety leaders are tasked with the responsibility of integrating these tools without creating instability in their internal workflows. This requires an evolutionary, rather than disruptive, approach. The most successful organizations are those that:
- Prioritize Human Relevance: Transitioning toward models that directly reflect human cardiac biology.
- Embrace Standardization: Participating in initiatives like AIMS to ensure that their data stands up to rigorous internal and external scrutiny.
- Engage Early: Utilizing regulatory dialogue platforms like ISTAND to ensure that their nonclinical data package aligns with the expectations of global regulatory bodies.
The Path Forward
The narrative of a "sudden" NAM shift is a myth; it is the culmination of years of painstaking scientific validation, investment in infrastructure, and cross-sector collaboration. The platforms now entering the mainstream—built on functional electrophysiology and validated by high-throughput, human-relevant data—offer a path forward that minimizes uncertainty.
As the industry looks toward the next decade, the integration of functional NAMs will likely move beyond cardiac safety into other therapeutic areas, including neurotoxicity and hepatotoxicity. Cardiac safety has provided the "blueprint" for how this transition should occur: by letting the science lead, the regulations follow, and the safety of the patient remains the ultimate, measurable outcome.
The era of "animal-first" is slowly giving way to an era of "human-relevant first." It is a shift that promises to bring safer, more effective therapies to market faster, ultimately fulfilling the promise of the FDA Modernization Act 2.0—not through a stroke of a pen, but through the rigorous, data-driven work of the scientists who have spent the last decade proving that the future of drug discovery is human.
About the Author
